Cytek Q2 Loss Deepens as Litigation Costs Surge Ahead of Trial

summarizeSummary

Cytek Biosciences posted a wider Q2 net loss of $12.2 million as litigation expenses surged ahead of an August 17 patent trial. Revenue rose 6%, but escalating operating costs, especially legal fees, are eroding profitability.

check_boxKey Events · Earnings and Guidance · CTKB

• Net Loss Widens

  The Q2 net loss reached $12.2M, compared with $5.6M a year ago, while the six-month loss widened to $31.0M from $17.0M. Higher G&A expenses, mainly litigation costs, drove the increase.

• Revenue Up 6%

  Total revenue hit $48.1M, with product revenue up 4% and service revenue up 10%. Gross margin improved to 59% from 52%, aided by a one-time $2.8M tariff refund.

• Litigation Costs Surge

  General and administrative expenses jumped 24% to $16.8M, primarily due to higher litigation-related expenses from the Beckman Coulter patent infringement case. A trial is scheduled for August 17, 2026.

• Cash Position

  Cash, equivalents, and marketable securities totaled $262.0M at quarter-end, down slightly from $261.5M at year-end. Operating activities used $1.4M in cash during the first half.

auto_awesomeAnalysis · CTKB · Industrial Applications And Services

A sharp rise in legal expenses tied to the Beckman Coulter patent dispute more than doubled Cytek's net loss to $12.2 million in Q2. While revenue grew 6% to $48.1 million, the bottom line is under heavy pressure from costs that show no sign of easing — a trial is set for August 17, 2026. Adding to the expense burden, the company disclosed a $365,775 severance payment to its former chief legal officer. The balance sheet remains solid with $262 million in cash and securities, but the litigation overhang and widening losses dominate the narrative.